Natalizumab is effective as second line therapy in the treatment of relapsing remitting multiple sclerosis

被引：37
作者：
Putzki, N. [1 ,2 ]
Kollia, K. [3 ]
Woods, S. [1 ]
Igwe, E. [1 ]
Diener, H. C. [1 ]
Limmroth, V. [1 ]
机构：
[1] Univ Duisburg Essen, Dept Neurol, D-45122 Essen, Germany
[2] Cantonal Hosp St Gallen, Dept Neurol, St Gallen, Switzerland
[3] Univ Hosp Essen, Dept Neuroradiol, Essen, Germany
来源：
EUROPEAN JOURNAL OF NEUROLOGY | 2009年 / 16卷 / 03期
关键词：
glatiramer acetate; interferon-beta; multiple sclerosis; natalizumab; treatment failure;
D O I：
10.1111/j.1468-1331.2008.02519.x
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
Natalizumab has been recommended for the treatment of patients with relapsing remitting multiple sclerosis with insufficient response to interferon-beta (IFN-beta) or glatiramer acetate (GA). Prospective, observational study. We found a reduction of the annualized relapse rate from 2.1 under IFN-beta or GA to 0.2 one year after switching to natalizumab. There were 94% fewer gadolinium enhancing lesions with natalizumab. Natalizumab reduced short term clinical and MRI activity in second line therapy and efficacy is comparable to first line therapy as demonstrated in the pivotal trials.
引用
收藏
页码：424 / 426
页数：3
相关论文
共 10 条
  • [1] Clinical course after change of immunomodulating therapy in relapsing-remitting multiple sclerosis
    Caon, C.
    Din, M.
    Ching, W.
    Tselis, A.
    Lisak, R.
    Khan, O.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2006, 13 (05) : 471 - 474
  • [2] Therapeutic outcome 3 years after switching of immunomodulatory therapies in patients with relapsing-remitting multiple sclerosis in Argentina
    Carra, A.
    Onaha, P.
    Luetic, G.
    Burgos, M.
    Crespo, E.
    Deri, N.
    Halfon, M.
    Jaacks, G.
    Lopez, A.
    Sinay, V.
    Vrech, C.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2008, 15 (04) : 386 - 393
  • [3] Non-specific immunosuppressants in the treatment of multiple sclerosis
    Confavreux, C
    Vukusic, S
    [J]. CLINICAL NEUROLOGY AND NEUROSURGERY, 2004, 106 (03) : 263 - 269
  • [4] Quantifying the risks and benefits of natalizumab in relapsing multiple sclerosis
    Dorsey, E. R.
    Thompson, J. P.
    Noyes, K.
    Dick, A. W.
    Holloway, R. G.
    Schwid, S. R.
    [J]. NEUROLOGY, 2007, 68 (18) : 1524 - 1528
  • [5] Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring
    Kappos, Ludwig
    Bates, David
    Hartung, Hans-Peter
    Havrdova, Eva
    Miller, David
    Polman, Chris H.
    Ravnborg, Mods
    Houser, Stephen L.
    Rudick, Richard A.
    Weiner, Howard L.
    O'Connor, Paul W.
    King, John
    Radue, Ernst Wilhelm
    Yousry, Tarek
    Major, Eugene O.
    Clifford, David B.
    [J]. LANCET NEUROLOGY, 2007, 6 (05) : 431 - 441
  • [6] A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis
    Polman, CH
    O'Connor, PW
    Havrdova, E
    Hutchinson, M
    Kappos, L
    Miller, DH
    Phillips, JT
    Lublin, FD
    Giovannoni, G
    Wajgt, A
    Toal, M
    Lynn, F
    Panzara, MA
    Sandrock, AW
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (09) : 899 - 910
  • [7] Current approved options for treating patients with multiple sclerosis
    Rizvi, SA
    Agius, MA
    [J]. NEUROLOGY, 2004, 63 (12) : S8 - S14
  • [8] Natalizumab plus interferon beta-1a for relapsing multiple sclerosis
    Rudick, RA
    Stuart, WH
    Calabresi, PA
    Confavreux, C
    Galetta, SL
    Radue, EW
    Lublin, FD
    Weinstock-Guttman, B
    Wynn, DR
    Lynn, F
    Panzara, MA
    Sandrock, AW
    Fazekas, F
    Enzinger, C
    Seifert, T
    Storch, M
    Strasser-Fuchs, S
    Berger, T
    Dilitz, E
    Egg, R
    Deisenhammer, F
    Decoo, D
    Lampaert, J
    Bartholome, E
    Bier, J
    Stenager, E
    Rasmussen, M
    Binzer, M
    Shorsh, K
    Christensen, M
    Ravnborg, M
    Sorensen, PS
    Blinkenberg, M
    Petersen, B
    Hansen, HJ
    Bech, E
    Petersen, T
    Kirkegaard, M
    Eralinna, J
    Ruutiainen, J
    Soilu-Hänninen, M
    Säkö, E
    Laaksonen, M
    Reunanen, M
    Remes, A
    Keskinarkaus, I
    Moreau, T
    Noblet, M
    Rouaud, O
    Couvreur, G
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (09) : 911 - 923
  • [9] Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy
    Yousry, TA
    Major, EO
    Ryschkewitsch, C
    Fahle, G
    Fischer, S
    Hou, J
    Curfman, B
    Miszkiel, K
    Mueller-Lenke, N
    Sanchez, E
    Barkhof, F
    Radue, EW
    Jager, HR
    Clifford, DB
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (09) : 924 - 933
  • [10] Glatiramer acetate in treatment-naive and prior interferon-β-1b-treated multiple sclerosis patients
    Zwibel, HL
    [J]. ACTA NEUROLOGICA SCANDINAVICA, 2006, 113 (06): : 378 - 386
1